Honeywell US to buy Johnson Matthey's catalyst business for $2.43 bn
Honeywell (NASDAQ: HON) announced that it has agreed to acquire Johnson Matthey's Catalyst Technologies business segment for £1.8 billion (~$2.43 billion) in an all-cash transaction, representing approximately 11x estimated 2025 EBITDA, inclusive of tax benefits and run-rate cost synergies. The combination of Johnson Matthey's Catalyst Technologies business with Honeywell's Energy and Sustainability Solutions (ESS) business segment is expected to add attractive high growth vectors to the portfolio and drive significant additional benefits through cost synergies.
Johnson Matthey's Catalyst Technologies' business model complements Honeywell's existing UOP business of selling catalyst and process technologies and expands its installed base across refining and petrochemical catalysts. In addition, with an expanded portfolio, Honeywell will for the first time be able to offer customers a comprehensive solution for the production of lower emission, critical fuels including sustainable methanol, sustainable aviation fuel (SAF), blue hydrogen and blue ammonia, which enhance energy security and reduce emissions. The resulting offerings will provide licensed technology, engineering, services and catalysts to convert hydrocarbon and renewable feedstocks to high-value end products.
Honeywell has agreed to acquire Johnson Matthey's Catalyst Technologies business for £1.8 billion (~$2.43 bn), enhancing its Energy and Sustainability Solutions portfolio. This acquisition will enable Honeywell to offer comprehensive solutions for lower emission fuels like SAF and blue hydrogen. The deal is expected to close by 1H 2026, boosting Honeywell's growth and synergies.
"The acquisition of Johnson Matthey's Catalyst Technologies business broadens Honeywell's role as a world-class technology provider of critical energy needed to drive growth into the future – further strengthening our model of combining process technologies and process automation," said Vimal Kapur, Chairman and CEO of Honeywell . "As demand for diversified sources of energy continues accelerating, we will better enable Honeywell to offer the innovation our customers need."
Johnson Matthey's Catalyst Technologies business segment is a leading provider of catalyst manufacturing and process technology licensing. It has approximately 1,900 employees and is headquartered in London, United Kingdom, with sites in the U.S., Europe and India.
"As we continue to expand and evolve our ESS portfolio, acquiring Johnson Matthey's Catalyst Technologies business will provide our customers a comprehensive and cost-effective approach to transition their businesses to high-value products with lower emissions," said Ken West, President and CEO of Honeywell's ESS segment . "Together, we will be able to create an integrated solution while also diversifying our UOP projects and service offerings to help our customers around the world continue innovating and driving energy security for the future."
The acquisition is expected to be accretive to earnings in the first year and will add attractive high growth vectors to Honeywell's ESS business.
The acquisition follows Honeywell's announcement of the planned spin-off of its Aerospace Technologies business along with the planned spin-off of its Advanced Materials business, which will result in three publicly listed industry leaders with distinct strategies and growth drivers.
Since December 2023, Honeywell has announced a number of strategic actions to drive organic growth and simplify its portfolio, including approximately $11 billion of accretive acquisitions recently closed or announced: the Access Solutions business from Carrier Global, Civitanavi Systems, CAES Systems, the LNG business from Air Products, and Sundyne. In addition, Honeywell entered into an agreement to divest its Personal Protective Equipment business, which is expected to close in Q2 2025. Honeywell remains on pace to exceed its commitment to deploy at least $25 billion toward high-return capital expenditures, dividends, opportunistic share purchases and accretive acquisitions through 2025.
Honeywell's acquisition of Johnson Matthey's Catalyst Technologies business segment is expected to close by 1H 2026, subject to customary closing conditions, including receipt of certain regulatory approvals. Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged.
Fibre2Fashion News Desk (MS)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
41 minutes ago
- Business Standard
Zydus to Enter Global Biologics CDMO Business Plans to Acquire Agenus' U.S. Manufacturing Facilities to Accelerate Development of Innovative Therapies
BusinessWire India New Jersey [US]/ Ahmedabad (Gujarat) [India], June 3: Zydus Lifesciences Ltd. (including its subsidiaries/affiliates, hereafter referred to as "Zydus) today announced its entry into the global biologics contract development and manufacturing organization (CDMO) business through its plan to acquire Agenus Inc.'s (Nasdaq: AGEN) U.S.-based biologics CMC facilities. This acquisition marks Zydus' strategic investment in U.S.-based manufacturing for biologics thereby adding a sustainable growth driver for the group. Agenus Inc. is a clinical-stage immuno-oncology company committed to developing immune therapies that effectively combat cancer. Under the terms of the agreement, Zydus will acquire two state-of-the-art biologics manufacturing facilities from Agenus in Emeryville and Berkeley, California (US) for an upfront consideration of US$75 million and contingent payment of US$50 million to be paid over three years subject to achievement of certain revenue milestone. This acquisition provides Zydus immediate access to advanced biologics manufacturing capabilities and establishes a key presence in California, a leading global biotechnology hub. This strategic move enables Zydus to leverage supply chain dynamics and a favourable geopolitical environment to expand its reach in the U.S. and globally. With this acquisition Zydus will now become a one stop solution provider across the entire development spectrum of biologics, right from pre-clinical to toxicology studies, clinical development and now manufacturing. Zydus' CDMO business will operate as an independent entity and will house the acquired manufacturing capabilities. The facilities come with an experienced professional team with strong capabilities and requisite industry expertise to deliver high-quality biologics development and manufacturing services to global biotech and pharmaceutical companies. As a part of transaction Zydus will become an exclusive contract manufacturer for Agenus and will provide manufacturing services for clinical and commercial supply of two identified Phase-3 ready immuno-oncology products, Botensilimab (BOT) and Balstilimab (BAL). Zydus will also have first right of negotiation to manufacture any of the future pipeline products developed by Agenus. Zydus intends to further expand the team and help create new jobs in the region and contribute to the local economy. Speaking on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Ltd. said, "The acquisition will give Zydus a strategic foothold in the U.S. for biologics manufacturing in the global hub for biotech innovation, California. It will enhance our ability to partner with innovation-centric entities, advancing new products and prioritizing patient-centric solutions. This move strengthens our long-term biologics vision and positions us to better serve the evolving needs of the global biopharmaceutical industry." The global biologics CDMO market is experiencing significant growth, driven by the increasing complexity of therapies, the rise of biologics in clinical pipelines, and a growing number of emerging biotech companies lacking internal manufacturing capabilities. According to the Global Biologics CDMO Market Size is expected to be worth around US$ 84.9 Billion by 2034, growing at a CAGR of 15.7% between 2025 to 2034. As demand surges for reliable, agile, and scalable partners, Zydus' entry into this space positions it to tap into significant long-term growth opportunities and support innovation across the global biopharmaceutical landscape.
Business Standard
an hour ago
- Business Standard
Praj Industries collaborates with IATA and ISMA
To advance SAF carbon assessment and certification in India India is taking decisive steps toward decarbonizing its aviation sector, with a SAF blending mandate targeting 1% by 2027 and 2% by 2028. In line with this national goal, Praj Industries, International Air Transport Association (IATA), and Indian Sugar & Bio-energy Manufacturers Association (ISMA) have signed a strategic Memorandum of Understanding (MoU) to drive the certification and adoption of Sustainable Aviation Fuel (SAF) in the country. The partnership will focus on conducting a comprehensive Life Cycle Assessment (LCA) of SAF derived from Indian sugarcane feedstock via the Ethanol to-Jet (ETJ) pathwaya critical milestone in demonstrating the environmental and economic viability of indigenous SAF solutions. The MoU underscores the participants' shared commitment to sustainability and to reducing emissions in aviationone of the world's most challenging sectors to decarbonize. Through this partnership, Praj, IATA, and ISMA aim to determine an accurate Carbon Intensity (CI) number for SAF produced using Indian sugarcane. CI measures the amount of greenhouse gas emissions produced per unit of energy generated (usually expressed in gCO₂e/MJ). This key metric for SAF determines how much cleaner the fuel is compared to conventional jet fuel. As part of the collaboration, the three participants will also work together to define and recommend a certification methodology suited to the Indian context. This framework will align with internationally recognized sustainability and emissions reduction standards, specifically the International Sustainability and Carbon Certification (ISCC) CORSIA and the Roundtable on Sustainable Biomaterials (RSB) CORSIA standard.
Business Standard
4 hours ago
- Business Standard
US stocks stay supported
The US stocks edged up in last session as broad focus stayed on trade talks. The Nasdaq climbed 128.85 points or 0.7 percent at 19,242.61, the S&P 500 rose 24.25 points or 0.4 percent to 5,935.94 and the Dow added 35.41 points or 0.1 percent to 42,305.38. Economic cues were tepid as the ISM said its manufacturing PMI eased to 48.5 in May from 48.7 in April, with a reading below 50 indicating contraction. With the decline, the manufacturing PMI dipped to its lowest level hitting 48.4 in November 2024. Meanwhile, the US Fed Chair Jerome Powell failed to comment on the US economic outlook amid market uncertainty due to Trump tariffs.
